| 2024-10-23 | 8-K | 10.1 | Sub-Sublease, by and between NewLimit, Inc. and Corvus Pharmaceuticals, Inc., dated as of October 22, 2024. |
|---|
| 2024-05-07 | 10-Q | 10.1 | Employment Agreement, dated as of February 2, 2024 by and between Corvus Pharmaceuticals, Inc. and Jeffrey S. Arcara. |
|---|
| 2024-05-06 | 8-K | 10.1 | Securities Purchase Agreement, dated May 1, 2024, between the Company and the Investors |
|---|
| 2023-08-08 | 10-Q | 10.2 | Amendment to Amended and Restated Employment Agreement, dated as of March 31, 2023, by and between Corvus Pharmaceuticals, Inc. and Richard A. Miller. |
|---|
| 2022-03-10 | 10-K | 10.18 | Open Market Sale Agreement, dated November 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC. |
|---|
| 2021-11-01 | 10-Q | 10.2 | Eighth Amendment to Office Lease, dated as of September 13, 2021, by and between Corvus Pharmaceuticals, Inc. and ARE 819/863 Mitten Road, LLC |
|---|
| 2021-11-01 | 10-Q | 10.1 | Sublease agreement, dates August 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Angel Pharmaceuticals US Inc. |
|---|
| 2020-10-29 | 10-Q | 10.2 | Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc. |
|---|
| 2020-07-30 | 10-Q | 10.2 | Transition and Consulting Agreement, dated June 30, 2020 by and between Corvus Pharmaceuticals, Inc. and Joseph Buggy |
|---|
| 2020-03-09 | 10-K | 10.18 | Exclusive License Agreement dated April 21, 2017, by and between Corvus Pharmaceuticals, Inc. and Monash University. |
|---|
| 2020-03-09 | 10-K | 10.17.B | Amendment No. 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc. |
|---|
| 2020-03-09 | 10-K | 10.16.B | Amendment No. 1 to the Phase I/IB Combination Study Agreement, dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc. |
|---|
| 2020-03-09 | 10-K | 10.16.C | Amendment No. 2 to the Phase I/IB Combination Study Agreement, dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc. |
|---|
| 2019-11-12 | 8-K | 10.1 | Exchange Agreement, dated November 8, 2019, by and among, Corvus Pharmaceuticals, Inc., Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P. and Biotechnology Value Trading Fund OS, L.P. |
|---|
| 2019-03-07 | 10-K | 10.11.A | Offer Letter, dated as of January 7, 2019 by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher. |
|---|
| 2019-03-07 | 10-K | 10.11.B | Change in Control and Severance Agreement, dated January 28, 2019, by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher. |
|---|
| 2019-03-07 | 10-K | 10.1.H | Seventh Amendment to Office Lease, dated as of October 11, 2018, by and between Corvus Pharmaceuticals, Inc. and ARE‑819/863 Mitten Road, LLC. |
|---|
| 2018-08-02 | 10-Q | 10.2 | Sixth Amendment to Office Lease dated as of April 5, 2018, by and between , Corvus Pharmaeuticals, Inc. and ARE-819/863 Mitten Road, LLC. |
|---|
| 2018-05-03 | 10-Q | 10.3 | Fifth Amendment to Office Lease dated as of March 2, 2018, by and between , Corvus Pharmaeuticals, Inc. and ARE-819/863 Mitten Road, LLC. |
|---|
| 2018-05-03 | 10-Q | 10.2 | Employment Agreement, dated November 26, 2014, by and between the Company and Joseph J. Buggy. |
|---|
| 2018-03-01 | 10-K | 10.9.A | Offer Letter, dated as of November 22, 2017 by and between Corvus Pharmaceuticals, Inc. and Daniel Hunt. |
|---|
| 2018-03-01 | 10-K | 10.9.B | Change in Control and Severance Agreement dated December 13, 2017, by and between Corvus Pharmaceuticals, Inc. and Daniel Hunt. |
|---|
| 2017-08-03 | 10-Q | 10.1 | Phase 1B/II combination study agreement dated May 1, 2017 by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc. |
|---|
| 2016-11-03 | 10-Q | 10.1.E | Fourth Amendment to Office Lease, dated as of August 15, 2016, by and between Corvus Pharmaceuticals, Inc. and ARE-819/863 Mitten Road, LLC. |
|---|
| 2016-08-04 | 10-Q | 10.3 | Change in Control and Severance Agreement, dated May 11, 2016, by and between Corvus Pharmaceuticals, Inc. and Jason Coloma. |
|---|
| 2016-08-04 | 10-Q | 10.2 | Offer Letter, dated as of April 28, 2016, by and between Corvus Pharmaceuticals, Inc. and Jason Coloma. |
|---|
| 2016-08-04 | 10-Q | 10.1.D | Third Amendment to Office Lease, dated as of June 27, 2016, by and between Corvus Pharmaceuticals, Inc. and ARE-819/863 Mitten Road, LLC. |
|---|